Identification of a single-dose, low flip angle based CBV threshold for fractional tumor burden (FTB) mapping in recurrent glioblastoma

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging

From the Department of Cancer Systems Imaging (A.A., C.C.Q.), and Department of Biostatistics (K.J.), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; Division of Neuroimaging Research and Barrow Neuroimaging Innovation Center (A.M.S.), Department of Neuroradiology (J.P.K.), and Department of Neuropathology (J.E.), Barrow Neurological Institute, Phoenix, Arizona, United States; Clinical Imaging Group (L.C.B.), Genentech Inc., South San Francisco, California, United States; Department of Biophysics (M.A.P., K.M.S.), Medical College of Wisconsin, Milwaukee, Wisconsin, United States; Department of Radiology (L.S.H.), Mayo Clinic, Phoenix, Arizona, United States; Department of Diagnostic Imaging (J.L.B.), Rhode Island Hospital, Providence, Rhode Island, United States. Laura C Bell is employed by Genentech Inc. Kathleen M. Schmainda has ownership interest in IQ-AI Ltd and Prism Clinical Imaging. Kathleen M. Schmainda has financial interest in Imaging Biometrics LLC. Kathleen M. Schmainda is a board member for Prism Clinical Imaging